ReviewOncology research and treatment2026
Genitourinary Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2025: Advances in Renal Cell Carcinoma and Muscle-Invasive Bladder Cancer.
Review in Oncology research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Background: At ESMO 2025, practice-changing advances in genitourinary oncology emerged for renal cell carcinoma (RCC) and muscle-invasive bladder cancer (MIBC), highlighting a shift toward early systemic treatment and biomarker-driven treatment selection. Summary: In localized RCC, the NESCIO trial showed pathologic responses with short-course neoadjuvant checkpoint inhibition, while the RAMPART study supported adjuvant dual checkpoint blockade for high-risk disease. For advanced RCC, the KEYMAKER-U03 trial demonstrated improved progression-free survival with a novel HIF-2α triplet regimen, and the LenCabo study supported the use of lenvatinib plus everolimus in later treatment lines. Conversely, the CALYPSO trial noted limited benefit when using empiric combinations without precise biomarker selection. In cisplatin-ineligible MIBC, the KEYNOTE-905/EV-303 trial demonstrated a significant survival benefit with perioperative enfortumab vedotin plus pembrolizumab. Finally, emerging data from OPTIC RCC transcriptomic stratification and circulating markers like kidney-injury molecule type 1 and circulating tumor DNA strongly support a broader transition toward tailored therapy. Key Messages: Perioperative enfortumab vedotin plus pembrolizumab offers a major survival benefit for cisplatin-ineligible bladder cancer patients. Overall, early-stage RCC benefits significantly from perioperative immunotherapy, while managing advanced disease requires a decisive shift away from empiric combinations and toward biomarker-driven treatment selection. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.